Moses Dodo
Director/Board Member at Starton Therapeutics, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Pedro Lichtinger | M | 70 |
Starton Therapeutics, Inc.
 Starton Therapeutics, Inc. BiotechnologyHealth Technology Starton Therapeutics, Inc. is a clinical-stage biotechnology platform company that focuses on transforming standard of care therapies with proprietary continuous delivery technology. The company is based in Paramus, NJ. The company's goal is to provide continuous treatment to people with cancer so they can live better and longer. Starton's proprietary transdermal technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. The company was founded in 2017 by Pedro Lichtinger, who has been the CEO since 2017. | 7 years |
| Nitin Kaushal | M | 58 |
Starton Therapeutics, Inc.
Starton Therapeutics, Inc. BiotechnologyHealth Technology Starton Therapeutics, Inc. is a clinical-stage biotechnology platform company that focuses on transforming standard of care therapies with proprietary continuous delivery technology. The company is based in Paramus, NJ. The company's goal is to provide continuous treatment to people with cancer so they can live better and longer. Starton's proprietary transdermal technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. The company was founded in 2017 by Pedro Lichtinger, who has been the CEO since 2017. | 6 years |
| Rapp Alyssa | F | 45 | - | |
| Eric Baum | M | 48 |
Starton Therapeutics, Inc.
Starton Therapeutics, Inc. BiotechnologyHealth Technology Starton Therapeutics, Inc. is a clinical-stage biotechnology platform company that focuses on transforming standard of care therapies with proprietary continuous delivery technology. The company is based in Paramus, NJ. The company's goal is to provide continuous treatment to people with cancer so they can live better and longer. Starton's proprietary transdermal technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. The company was founded in 2017 by Pedro Lichtinger, who has been the CEO since 2017. | 6 years |
| Roy F. Waldron | M | 61 |
Starton Therapeutics, Inc.
Starton Therapeutics, Inc. BiotechnologyHealth Technology Starton Therapeutics, Inc. is a clinical-stage biotechnology platform company that focuses on transforming standard of care therapies with proprietary continuous delivery technology. The company is based in Paramus, NJ. The company's goal is to provide continuous treatment to people with cancer so they can live better and longer. Starton's proprietary transdermal technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. The company was founded in 2017 by Pedro Lichtinger, who has been the CEO since 2017. | 5 years |
| George Hornig | M | 69 | - | |
| Fotios Plakogiannis | M | 90 |
Starton Therapeutics, Inc.
Starton Therapeutics, Inc. BiotechnologyHealth Technology Starton Therapeutics, Inc. is a clinical-stage biotechnology platform company that focuses on transforming standard of care therapies with proprietary continuous delivery technology. The company is based in Paramus, NJ. The company's goal is to provide continuous treatment to people with cancer so they can live better and longer. Starton's proprietary transdermal technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. The company was founded in 2017 by Pedro Lichtinger, who has been the CEO since 2017. | - |
| John MacCarthy | M | 64 | - | |
| Kenneth Anderson | M | 72 |
Starton Therapeutics, Inc.
Starton Therapeutics, Inc. BiotechnologyHealth Technology Starton Therapeutics, Inc. is a clinical-stage biotechnology platform company that focuses on transforming standard of care therapies with proprietary continuous delivery technology. The company is based in Paramus, NJ. The company's goal is to provide continuous treatment to people with cancer so they can live better and longer. Starton's proprietary transdermal technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. The company was founded in 2017 by Pedro Lichtinger, who has been the CEO since 2017. | 4 years |
| Asher Chanan-Khan | M | 55 |
Starton Therapeutics, Inc.
Starton Therapeutics, Inc. BiotechnologyHealth Technology Starton Therapeutics, Inc. is a clinical-stage biotechnology platform company that focuses on transforming standard of care therapies with proprietary continuous delivery technology. The company is based in Paramus, NJ. The company's goal is to provide continuous treatment to people with cancer so they can live better and longer. Starton's proprietary transdermal technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. The company was founded in 2017 by Pedro Lichtinger, who has been the CEO since 2017. | - |
| Mohamad Hussein | M | - |
Starton Therapeutics, Inc.
Starton Therapeutics, Inc. BiotechnologyHealth Technology Starton Therapeutics, Inc. is a clinical-stage biotechnology platform company that focuses on transforming standard of care therapies with proprietary continuous delivery technology. The company is based in Paramus, NJ. The company's goal is to provide continuous treatment to people with cancer so they can live better and longer. Starton's proprietary transdermal technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. The company was founded in 2017 by Pedro Lichtinger, who has been the CEO since 2017. | - |
| Scott Kahn | M | 62 | - | |
| James Oliver | M | 68 | - | |
| Andrew Rensink | M | 68 | 6 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Cidnee Vaykovich | F | - |
Starton Therapeutics, Inc.
Starton Therapeutics, Inc. BiotechnologyHealth Technology Starton Therapeutics, Inc. is a clinical-stage biotechnology platform company that focuses on transforming standard of care therapies with proprietary continuous delivery technology. The company is based in Paramus, NJ. The company's goal is to provide continuous treatment to people with cancer so they can live better and longer. Starton's proprietary transdermal technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. The company was founded in 2017 by Pedro Lichtinger, who has been the CEO since 2017. | 6 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 9 | 60.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Moses Dodo
- Personal Network
